574 related articles for article (PubMed ID: 7737671)
1. Chimerization of LL2, a rapidly internalizing antibody specific for B cell lymphoma.
Leung SO; Shevitz J; Pellegrini MC; Dion AS; Shih LB; Goldenberg DM; Hansen HJ
Hybridoma; 1994 Dec; 13(6):469-76. PubMed ID: 7737671
[TBL] [Abstract][Full Text] [Related]
2. Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2.
Leung SO; Goldenberg DM; Dion AS; Pellegrini MC; Shevitz J; Shih LB; Hansen HJ
Mol Immunol; 1995 Dec; 32(17-18):1413-27. PubMed ID: 8643111
[TBL] [Abstract][Full Text] [Related]
3. Cloning of cDNAs encoding the variable domains of antibody BrE-3 and construction of a chimeric antibody.
Couto JR; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1993 Feb; 12(1):15-23. PubMed ID: 8454302
[TBL] [Abstract][Full Text] [Related]
4. Cloning of cDNAs encoding the variable domains of antibody KC4G3 and construction of a chimeric antibody.
Couto JR; Blank EW; Peterson JA; Ceriani RL
Hybridoma; 1993 Aug; 12(4):485-9. PubMed ID: 8244420
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2.
Losman MJ; Leung SO; Shih LB; Shevitz J; Shukla R; Haraga L; Goldenberg DM; Hansen HJ
Cancer Res; 1995 Dec; 55(23 Suppl):5978s-5982s. PubMed ID: 7493380
[TBL] [Abstract][Full Text] [Related]
6. Effect of VK framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site.
Leung SO; Dion AS; Pellegrini MC; Losman MJ; Grebenau RC; Goldenberg DM; Hansen HJ
Int J Cancer; 1995 Feb; 60(4):534-8. PubMed ID: 7829269
[TBL] [Abstract][Full Text] [Related]
7. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody.
Juweid M; Sharkey RM; Markowitz A; Behr T; Swayne LC; Dunn R; Hansen HJ; Shevitz J; Leung SO; Rubin AD
Cancer Res; 1995 Dec; 55(23 Suppl):5899s-5907s. PubMed ID: 7493367
[TBL] [Abstract][Full Text] [Related]
8. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.
Sharkey RM; Behr TM; Mattes MJ; Stein R; Griffiths GL; Shih LB; Hansen HJ; Blumenthal RD; Dunn RM; Juweid ME; Goldenberg DM
Cancer Immunol Immunother; 1997 May; 44(3):179-88. PubMed ID: 9191878
[TBL] [Abstract][Full Text] [Related]
9. Mouse/human chimeric Me1-14 antibody: genomic cloning of the variable region genes, linkage to human constant region genes, expression, and characterization.
Batra SK; Niswonger ML; Wikstrand CJ; Pegram CN; Zalutsky MR; Morrison SL; Bigner DD
Hybridoma; 1994 Apr; 13(2):87-97. PubMed ID: 8050781
[TBL] [Abstract][Full Text] [Related]
10. cDNA sequence analysis of monoclonal antibody FU-MK-1 specific for a transmembrane carcinoma-associated antigen, and construction of a mouse/human chimeric antibody.
Arakawa F; Yamamoto T; Kanda H; Watanabe T; Kuroki M
Hybridoma; 1999 Apr; 18(2):131-8. PubMed ID: 10380012
[TBL] [Abstract][Full Text] [Related]
11. The construction of a mouse/human chimeric antibody against human breast cancer cells.
Meulemans E; Vandevyver C; Volckaert G; Raus J
Year Immunol; 1993; 7():131-6. PubMed ID: 8372502
[No Abstract] [Full Text] [Related]
12. Construction and expression of two mouse-human chimeric antibodies with high specificity and affinity for carcinoembryonic antigen.
Arakawa F; Haruno M; Kuroki M; Kanda H; Watanabe T; Misumi Y; Matsuoka Y
Hybridoma; 1993 Aug; 12(4):365-79. PubMed ID: 8244416
[TBL] [Abstract][Full Text] [Related]
13. Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma.
Arndt MA; Krauss J; Schwarzenbacher R; Vu BK; Greene S; Rybak SM
Int J Cancer; 2003 Dec; 107(5):822-9. PubMed ID: 14566834
[TBL] [Abstract][Full Text] [Related]
14. The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2.
Sutton VR; Burgess J; Pietersz GA; Li WJ; McKenzie IF; Trapani JA
Ther Immunol; 1994 Apr; 1(2):83-93. PubMed ID: 7584487
[TBL] [Abstract][Full Text] [Related]
15. Chimeric anti-ganglioside GM2 antibody with antitumor activity.
Nakamura K; Koike M; Shitara K; Kuwana Y; Kiuragi K; Igarashi S; Hasegawa M; Hanai N
Cancer Res; 1994 Mar; 54(6):1511-6. PubMed ID: 8137257
[TBL] [Abstract][Full Text] [Related]
16. Production and functional characterization of two mouse/human chimeric antibodies with specificity for the tumor-associated Tn-antigen.
Oppezzo P; Osinaga E; Tello D; Bay S; Cantacuzene D; Irigoín F; Ferreira A; Roseto A; Cayota A; Alzari P; Pritsch O
Hybridoma; 2000 Jun; 19(3):229-39. PubMed ID: 10952411
[TBL] [Abstract][Full Text] [Related]
17. Chimeric murine-human antibodies directed against folate binding receptor are efficient mediators of ovarian carcinoma cell killing.
Coney LR; Mezzanzanica D; Sanborn D; Casalini P; Colnaghi MI; Zurawski VR
Cancer Res; 1994 May; 54(9):2448-55. PubMed ID: 7512887
[TBL] [Abstract][Full Text] [Related]
18. Binding activities and antitumor properties of a new mouse/human chimeric antibody specific for GD2 ganglioside antigen.
Alvarez-Rueda N; Leprieur S; Clémenceau B; Supiot S; Sébille-Rivain V; Faivre-Chauvet A; Davodeau F; Paris F; Barbet J; Aubry J; Birklé S
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5613s-5620s. PubMed ID: 17875797
[TBL] [Abstract][Full Text] [Related]
19. Construction and expression of chimeric antibodies by a simple replacement of heavy and light chain V genes into a single cassette vector.
Kanda H; Mori K; Koga H; Taniguchi K; Kobayashi H; Sakahara H; Konishi J; Endo K; Watanabe T
Hybridoma; 1994 Oct; 13(5):359-66. PubMed ID: 7860092
[TBL] [Abstract][Full Text] [Related]
20. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49.
Kashmiri SV; Shu L; Padlan EA; Milenic DE; Schlom J; Hand PH
Hybridoma; 1995 Oct; 14(5):461-73. PubMed ID: 8575795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
